Related Experiment Videos
Cytochrome P450-based cancer gene therapy: current status
On Kan1, Susan Kingsman, Stuart Naylor
1Oxford BioMedica (UK) Ltd, Medawar Centre, Oxford Science Park, Oxford OX4 4GA, UK.
Expert Opinion on Biological Therapy
|January 9, 2003
Summary
P450-based gene-directed enzyme prodrug therapy (GDEPT) shows promise for cancer treatment. Clinical trials indicate this safe and effective strategy is advancing, with future enhancements planned for gene delivery and prodrug development.
Area of Science:
- Oncology
- Gene Therapy
- Pharmacology
Background:
- Preclinical studies confirm the safety and efficacy of P450-based gene-directed enzyme prodrug therapy (GDEPT) for cancer treatment.
- The P450-GDEPT strategy has successfully transitioned from preclinical research into clinical trials.
Purpose of the Study:
- To evaluate the clinical safety and efficacy of P450-based GDEPT using various delivery methods, P450 isoforms, and prodrugs.
- To assess the encouraging outcomes from Phase I/II clinical trials of this novel cancer therapy.
Main Methods:
- Two distinct GDEPT approaches were employed: retroviral vector MetXia and encapsulated P450-expressing cells.
- Clinical trials utilized different cytochrome P450 isoforms (CYP2B6, CYP2B1) and prodrugs (cyclophosphamide, ifosfamide).
Main Results:
- Phase I/II clinical trials for P450-based GDEPT have concluded.
- Encouraging results were observed in the conducted clinical trials, supporting the therapeutic potential of this strategy.
Conclusions:
- P450-based GDEPT is a safe and efficacious strategy for cancer treatment, as evidenced by clinical trial data.
- Future research will focus on enhancing gene delivery vectors and targeted gene expression for improved therapeutic outcomes.
- Development of synthetic P450s and novel prodrugs offers further potential to optimize enzyme kinetics and active moiety profiles.